48 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
biotechnology industry and society at large.
EXECUTIVE AND DIRECTOR COMPENSATION
Executive Officers
Certain information regarding our executive
424B5
SYRS
Syros Pharmaceuticals Inc.
19 Dec 23
Prospectus supplement for primary offering
4:53pm
, who are not suitable candidates for standard intensive chemotherapy.
At the 62nd American Society of Hematology Annual Meeting and Exposition held
8-K
EX-99.1
lkkcr9y9 s2qy1dlsa1
25 May 23
Regulation FD Disclosure
5:10pm
8-K
EX-99.2
f02dhm17sx97 75l7r
25 May 23
Regulation FD Disclosure
5:10pm
8-K
EX-99.2
v0wpi8eyhm53da7lcs69
12 Dec 22
Regulation FD Disclosure
7:48am
8-K
1fkrj 8ox4ps
12 Dec 22
Regulation FD Disclosure
7:48am
425
rp8g ofjqu32
5 Jul 22
Business combination disclosure
7:14am
8-K
EX-2.1
r65 ztf6kf
5 Jul 22
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7:07am